Private equity firm Creador is in advanced talks to acquire a 10% stake in Leeford Healthcare for ₹800 crore. This deal would mark the first external investment for the promoter-owned Indian drugmaker, valuing the company at up to ₹8,500 crore.
Kuala Lumpur-based private equity investor Creador is currently in advanced discussions to purchase approximately 10% of Leeford Healthcare. If finalized, the transaction is expected to be valued at around ₹800 crore, setting the total valuation of the Indian pharmaceutical company between ₹8,000 crore and ₹8,500 crore.
First External Capital Entry
For Leeford Healthcare, which has been entirely owned by the promoter family of Jiwan Lal Gupta since its founding in 2006, this move would represent its first dilution of equity to an outside investor. The company has built a wide business footprint over the last two decades, managing a product list that includes more than 2,000 items. Its operations range from standard generic drugs and prescription medicines to personal care products under the brand Cosmacia and wellness offerings.
Financial Context and Growth
The interest from Creador comes after the firm’s recent entry into the Indian healthcare space through a stake purchase in La Renon Healthcare in late 2025. Leeford Healthcare has reported steady financial growth in recent periods. For the fiscal year that ended in March 2025, the company recorded a revenue of $204.7 million, reflecting a 5% year-on-year increase. More notably, its net profit grew by 27% to $28.4 million, while its operating profit—measured as Ebitda—rose 24% to $40.5 million.
Operational Scope and Future Trackers
Leeford currently operates ten manufacturing facilities across India that produce a variety of formulations, cosmetics, and Ayurvedic products. Beyond its core pharmacy business, the company has also expanded into Leeford Medi Sciences, a unit dedicated to high-growth areas like nephrology and urology. It also maintains a presence in the orthopedics and mobility aids market, along with export operations.
Investors will now watch for official confirmation of the stake sale and the final valuation terms agreed upon by both parties. Key monitorables for the company’s long-term health will include its ability to maintain the reported 27% profit growth as it integrates external capital and whether it accelerates its plans for specialized therapies in the nephrology and urology segments.